Prothena (NASDAQ: PRTA) insider buys $1.82 million of shares, lifts stake

Posted by Ethan Ryder on Oct 9th, 2026

What happened

Prothena Corp Public Ltd Co (NASDAQ: PRTA) filed a Form 4 on 2026-10-09 showing 10% owner William P. Scully bought 215,000 shares.

The Form 4 breaks the buy into two tranches, 125,000 shares on 2026-10-07 and 90,000 shares on 2026-10-08. The average prices were $8.4012 for the first block and $8.5656 for the second. The filing lists the shares as indirect ownership through a spouse. Together, the purchases totaled about $1.82 million, and Scully held 529,000 shares after the trades.

Key numbers

Metric	Latest	Source
Shares bought	215,000 shares	SEC Form 4
Purchase price range	$8.40 to $8.57 per share	SEC Form 4
Total purchase value	about $1.82 million	SEC Form 4
Shares held after trade	529,000 shares	SEC Form 4

Read more: Prothena Corp Public (PRTA) stock analysis and investment case

Why it matters

OptimistFi's case is that PRTA is a cash-funded clinical-option story, so durable value depends on whether Prothena's protein-dysregulation expertise can produce approvable or partnerable therapies before burn erodes the balance sheet. A 10% owner adding stock strengthens that lens because the position grew rather than shrank. The move is large enough to matter because it came from a 10% owner, not a small holder.

That 215,000-share buy was about 68.5% of the holding before the trade, implying 314,000 shares before the purchase. The post-trade holding of 529,000 shares gives the move size and puts the commitment in context. One buy from one 10% owner is only a snapshot of stance, not proof of pipeline or financing progress.

Browse: stock research on every company OptimistFi covers

What's next

Prothena's next quarterly report is the next scheduled test for investors tracking whether cash use still leaves room for the clinical plan. That report will matter most if it shows the balance sheet still supports development work while the pipeline keeps moving. Investors will judge it against the same cash-and-catalyst problem.

The quarterly report will be the first dated follow-up investors can compare with this purchase. If it confirms that balance-sheet support, the Form 4 looks more supportive of the stock. If burn outruns progress, this purchase will read more like a snapshot of one investor's view than a change in the company story.